Skip to main content
Clinical Trials/NCT02386163
NCT02386163
Completed
Not Applicable

Large-scale ex Vivo Expansion and Characterization of Synovial Membrane MSC (SM-MSC) and Infrapatellar Fat Pad MSC (IF-MSC) for Clinical Application

EMO Biomedicine Corporation1 site in 1 country6 target enrollmentMay 2014
ConditionsKnee Injuries

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Knee Injuries
Sponsor
EMO Biomedicine Corporation
Enrollment
6
Locations
1
Primary Endpoint
Compare MSCs from synovial membrane and infrapatellar fat pad
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

According to many researches, mesenchymal stem cells (MSC) isolated from synovial membrane and infrapatellar fat pad have higher ex vivo proliferation capacity, multipotency and ability to undergo chondrogenesis.

Based on this concept, the investigators plan to get two removed tissues (synovial membrane and infrapatellar fat pad) from patients who have an operation of TKR (Total Knee Replacement). The investigators are going to isolate and expand MSC from these two tissues respectively, and then compare their characterization and potential for clinical application. In the other hand, the investigators plan to build techniques and procedures which comply with "Good Tissue Practices (GTP)".

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
August 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
EMO Biomedicine Corporation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient who have an total knee replacement surgery

Exclusion Criteria

  • Patient who don't sign the agreement

Outcomes

Primary Outcomes

Compare MSCs from synovial membrane and infrapatellar fat pad

Time Frame: 2 months

Comparison items include doubling time, phenotype, chondrogenesis and biological activity.

Study Sites (1)

Loading locations...

Similar Trials